Publication | Open Access

Southwest Oncology Group Phase II Trial (S0341) of Erlotinib (OSI-774) in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2

MedicineMetronomic TherapyPathologyBronchial NeoplasmPerformance StatusCancer TreatmentOncologyRadiation OncologyLung Cancer